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Recent studies have identified more than 160 inflammatory
bowel disease susceptibility loci and provided evidence for
genetic heritability in disease pathogenesis. Here we
describe a case of a 47-year-old White woman suffering
from Crohn’s disease (CD), who had four children, two with
CD and two with a factor V Leiden variation. We analysed
the presence of single nucleotide polymorphisms in
several CD susceptibility genes. SNP analysis was carried
out using commercially available assays. The female CD
patient had a positive inflammatory bowel disease family
history. All of the patients had a mild disease course,
without fistulae or symptomatic stenosis. The patient was
heterozygous for risk variants of the genes encoding
nucleotide oligomerization domain 2 (NOD2) and Toll-like
receptor 5 (TLR5) and a homozygous carrier of both of the
identified protein tyrosine phosphatase nonreceptor type 2
(PTPN2) risk alleles. The CD-affected daughter carried
heterozygous risk alleles of the genes encoding TLR5,
NOD2 and PTPN2. The son, with the earliest onset of
disease in the family at the age of 12 years, was
heterozygous for risk alleles of autophagy 16 like 1
(ATG16L1), TLR5, NOD2 and PTPN2. This study
reports an interesting pattern of CD-associated single
nucleotide polymorphisms in a family with CD. This report
clearly supports the observation that genetic variations,
especially in genes associated with the innate immune
system, contribute to disease onset. Eur J Gastroenterol
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Introduction
Inflammatory bowel disease (IBD) is a chronic inflamma-
tory disease of the gastrointestinal tract, which includes
Crohn’s disease (CD) and ulcerative colitis (UC). CD is
characterized by a chronic and transmural inflammation
that can occur anywhere in the gastrointestinal tract.
Environmental and genetic factors, as well as aberrant
immune responses, have been considered as the major
aetiologies of IBD and CD in particular. Evidence suggests
that an epithelial barrier defect, coupled with a dysfunc-
tional immune response of the innate as well as the
acquired immune system to commensal microbiota, resulting
in either excessive upregulation or impaired downregula-
tion of inflammatory events, drives the development of
chronic intestinal inflammation [1]. The predispositions
are genetically determined, and genetic variations, mean-
ing single nucleotide polymorphisms (SNPs), in more
than 160 gene loci have been associated with IBD [2,3].
On the basis of population-based studies and incidence
cohorts, it has been well confirmed and demonstrated
that there is a heritability for IBD, and relatives of an IBD
patient have a significantly higher risk of also developing
IBD as compared with the general population [4]. In CD,
a large meta-analysis of genome-wide association studies
has identified at least 71 replicated loci (meaning that
they have been found in at least two independent
studies), such as nucleotide oligomerization domain 2
(NOD2), autophagy 16 like 1 (ATG16L1), immunity-
related GTPase family M protein (IRGM), Toll-
like receptor 5 (TLR5), protein tyrosine phosphatase
nonreceptor type 2 (PTPN2) and PTPN22 [5]. However,
despite increasing knowledge about the functional
relevance of these genes in the cellular and molecular
context, the relevance of the presence of these mutations
with respect to the onset of IBD is still unclear.
Here we report the case of a 47-year-old White woman
suffering from CD, who had four children, two also with
CD and two with factor V Leiden, and we analyse the
presence of several important CD susceptibility genes by
SNP analysis.
Case report
In April 2010, a 44-year-old female patient was admitted
for active CD with abdominal pain and diarrhoea. Her
current medication was steroids and azathioprine.
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The patient was first diagnosed with CD in 2009 at the
age of 43 years on the basis of radiological examination,
colonoscopy and clinical presentation. She was a persis-
tent smoker with a 30 pack-year history. Upon treatment
with steroids and mesalazine (5-ASA) an improvement in
disease activity was achieved. The therapy with mesala-
zine had to be stopped because of a general exanthema.
Six months later another acute flare of CD had to be
treated with steroids, and maintenance treatment with
azathioprine was started. On treatment with azathioprine,
stable remission was achieved and is still persistent.
Interestingly, the patient had a positive family history of
CD and UC. The father of the patient had been
diagnosed with UC and developed colorectal cancer in
1990. The patient is married and has four children. Two
of them were also diagnosed with CD and two have
a factor V Leiden mutation. The patient’s husband and
father of her children neither suffers from IBD nor has a
factor V Leiden mutation; however, he had undergone
a kidney transplantation for end-stage kidney dysfunction
due to glomerulonephritits.
One daughter was diagnosed with CD in 2011 at the age
of 21 years. One son was diagnosed with CD in 2005
at the age of 12 years. Although both of them developed
the disease at a young age, both of them have had a mild
disease course so far with only azathioprine as main-
tenance therapy. Both children with factor V Leiden have
had no complications until now. None of the family
members have suffered from fistulae or relevant
intestinal stenosis so far (Fig. 1). To the best of our
knowledge, the two daughters without CD have not
undergone endoscopy.
Genotyping
Given the family history, a genetic component of the
disease seems obvious. To address the involvement of
genetic variations, the patient, her husband and all her
children were genotyped for eight common IBD-associated
risk alleles in the gene loci encoding NOD2 (SNP-8,
rs2066844; SNP-12, rs2066845), TLR5 (SNP ID:
rs5744168), ATG16L1 (SNP ID: rs2241880), IRGM (SNP
ID: rs4958847), PTPN22 (SNP ID: rs2476601; SNP ID:
rs33996649) and PTPN2 (SNP ID: rs2542151; SNP ID
rs1893217). Genomic DNA was isolated from freshly
collected blood samples using the QIAmp DNA Blood
Minikit (Qiagen, Hilden, Germany). The variants were
determined using commercially available SNP Genotyping
Assays (Applied Biosystems, Carlsbad, California, USA) and
TaqMan Genotyping Master Mix (Applied Biosystems) on
a 7900HT Fast Real-Time PCR System using SDS 2.2
Software (Applied Biosystems).
Discussion
The detected variants are all linked to host response to
bacteria. NOD2 is an intracellular receptor recognizing
the bacterial cell wall component muramyl dipeptide and
is crucially involved in the initiation of an adequate host
defence against invading pathogens [6]. Variants of NOD2
have been identified as a prominent susceptibility factor
Fig. 1
UC Non-IBD
Non-IBD
CD
Birth 1966
ED 2009
CD
Birth 1990
ED 2011
CD
Birth 1993
ED 2005
Factor V
Leiden
Birth 1983
Factor V
Leiden
Birth 1986
The family tree shows the IBD history of the family in a schematic manner. Male family members are represented by a rectangle, female family
members by an ellipse. CD, Crohn’s disease; ED, diagnosis; IBD, inflammatory bowel disease; UC, ulcerative colitis.
804 European Journal of Gastroenterology & Hepatology 2014, Vol 26 No 7
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
for IBD [7], and loss of function results in defective
immune response and ineffective bacterial handling.
Interestingly, we only found a variation in the NOD2
SNP-8, but not in SNP-12.
ATG16L1 is a protein involved in autophagy modulation
and the CD-associated T300A allele results in defective
autophagy [8,9]. Autophagy is an important cellular
survival mechanism, but it is also involved in degradation
and clearance of intracellular bacteria and effective
antigen presentation. Further, it is linked at a functional
level to NOD2 and both of them can directly interact to
control the initiation of the adaptive immune response
against invading bacteria [10,11]. Although the presence
of the heterozygous ATG16L1 variation is rather common,
even among healthy individuals, we found it only in the
son affected with CD, in the healthy father and in one of
the daughters without CD.
TLR5 is an extracellular receptor sensing the conserved
bacterial product flagellin. Defective TLR5 signalling
results in poor proinflammatory response to enteric
bacteria and variants are negatively associated with
IBD [12]. The heterozygous variation was found in all
family members affected by CD and also in one of the
daughters without CD.
PTPN2 is a protein that controls proinflammatory signal-
ling cascades, including pathways downstream of NOD2,
and is involved in autophagy regulation [13]. The two IBD-
associated variants result in the expression of a dysfunc-
tional protein that is ineffective in the regulation of
proinflammatory signalling pathways [14]. Interestingly, the
mother was a homozygous carrier of both of the IBD risk
variants. All of her children were heterozygous for both of
these variations.
None of the family members had a homozygous or
heterozygous variation within the IBD-associated auto-
phagy gene, IRGM, nor within the PTPN22 gene. The lack
of variations within the PTPN22 gene, which is also
involved in the regulation of NOD2 signalling and
autophagy [15], in the CD patients is also of interest, as
both of the variants are reported to protect from IBD [16].
Within the patient’s family we found an interesting
distribution of the risk variants with an accumulation in
the CD-affected members: the index patient is hetero-
zygous for risk variants of the genes encoding the
pathogen sensors NOD2 and TLR5, and is a homozygous
carrier of both of the PTPN2 risk alleles. The CD-
affected daughter carries one risk allele of both TLR5 and
NOD2 and is heterozygous for both of the risk alleles of
PTPN2. The son, with the earliest onset of disease in the
family, has risk variants of all IBD-associated SNPs
detected within the family: he is heterozygous for the
risk alleles of ATG16L1, TLR5 and NOD2, as well as both
of the risk alleles of PTPN2. The father carries the risk
variant of ATG16L1 but none of the other analysed SNPs.
The nonaffected daughters are both heterozygous for the
risk alleles of PTPN2 and carry either the risk variant of
ATG16L1 or TLR5 but no variant of NOD2 (Table 1).
These observations seem to support the hypothesis that
an accumulation of several genetic variations within an
individual increases the risk for developing CD.
Interestingly, both of the children without CD carry a
factor V Leiden mutation, which represents a genetic
disorder characterized by a poor anticoagulant response to
activated protein C and a high risk for venous thrombo-
embolism. Deep venous thrombosis and pulmonary em-
bolism are the most common manifestations. The clinical
expression of a factor V Leiden mutation is influenced by
a number of factor V Leiden alleles, coexisting genetic
and acquired thrombophilic disorders and also circum-
stantial risk factors [17,18].
Thromboembolism is a well-described complication of
IBD but knowledge about its possible role in the
manifestation of this disease is still poor. The incidence
fluctuates between 1 and 6% in clinical studies and 7 and
39% in autopsy studies [19–21]. The aetiology of
thrombosis in IBD is multifactorial, but the exact
mechanism remains unknown [22]. Several acquired
prothrombotic risk factors include the inflammatory process
per se, use of corticosteroids, surgical treatment, smoking
and the use of oral contraceptives [23]. Genetic factors may
also play a role in thrombosis in IBD patients. One of the
most common genetic variants that affects the risk for
thrombosis is factor V Leiden [21,24]. During the last few
years there have been several studies assessing whether
there is an association between factor V Leiden mutation
and CD: in the study by Liebman et al. [21], a factor V
Leiden mutation was found in 36% of 11 IBD patients with
a history of thromboembolism and in 4% of 51 IBD patients
Table 1 Genetic variations within the family members
ATG16L1 TLR5 IRGM PTPN2_1 PTPN2_2 PTPN22_20 PTPN22_30 NOD2_8 NOD2_12
G/G G/G G/G T/T A/A G/G C/C C/C G/G
Father G/A G/G G/G G/T A/A G/G C/C C/C G/G
Mother G/G G/A G/G G/G G/G G/G C/C C/T G/G
Daughter G/G G/A G/G G/T A/G G/G C/C C/T G/G
Daughter G/A G/G G/G G/T A/G G/G C/C C/C G/G
Daughter G/G G/A G/G G/T A/G G/G C/C C/C G/G
Son G/A G/A G/G G/T A/G G/G C/C C/T G/G
Line 2 represents the wild-type variant of each SNP. CD-affected individuals are represented in light grey.
CD, Crohn’s disease; SNP, single nucleotide polymorphism.
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with no history of thromboembolism. Another study
showed that factor V Leiden and prothrombin G20282A
gene mutations were increased in IBD patients with a
history of thromboembolism compared with IBD patients
without a history of thromboembolism [21].
However, the limitation of our study is that we only present
a single case of an interesting accumulation of CD cases in
one single family. The two daughters without CD have a
rather similar pattern of SNPs compared with the one
daughter diagnosed with CD. Therefore, from our study, it
is not possible to propose definite associations between the
presence of a certain number of CD-associated SNPs and
the onset of disease. Although our study highlights the role
of genetic variations in the pathogenesis of CD, it is not
sufficient to make significant associations between a
genetic pattern consisting of a variety of CD-associated
risk genes and the onset of CD.
Taken together, this family represents an interesting
pattern of SNPs associated with CD and factor V Leiden.
CD-affected family members accumulate several IBD-
associated risk alleles of genes associated with the innate
immune system. These observations clearly support the
concept of genetic heritability in CD and underline
the importance for further studies to identify the func-
tional role of the IBD risk genes in the context of IBD
pathogenesis.
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